A Year Of Surprises Shakes Up Industry Top 10
Sandoz, Mylan And Teva Switch Places At The Top
In an eventful year for the off-patent industry, the world’s leading generics and biosimilars players have switched places in Generics Bulletin’s newly-compiled global sales ranking.
You may also be interested in...
After an extraordinary year that saw demand patterns and the supply chain upended by the COVID-19 pandemic, as well as a major merger that has transformed one of the global off-patent industry’s biggest players, the leaders of the pack in the Generics Bulletin Top 50 have once again seen significant changes in 2021.
This article brings you a compilation of all the data from Generics Bulletin's recent ranking of the top 50 generics and biosimilars companies, including additional details of how the financial figures stack up.
In the third and final part of Generics Bulletin’s newly-compiled global sales ranking of generics and biosimilars companies, one or two new entrants appeared towards the bottom of the top 50.